EWNYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends December 31
Edwards Lifesciences Corp
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$87.22+0.62 (+0.72%)
Close on Oct 19, 2026
- Market cap
- $50.38B
- P/E (TTM)
- 50.1
- Dividend yield
- –
Edwards Lifesciences Corp revenue by segment
By business segment
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $1.00B | $937.60M | $907.00M | $907.50M | $889.70M | $838.90M | $812.90M | $804.60M | $806.40M | $782.10M | $744.30M | $735.90M | 57.6% | +12.8% |
| Europe | $439.60M | $442.60M | $409.60M | $387.90M | $378.20M | $341.80M | $343.70M | $319.80M | $332.20M | $326.00M | $302.20M | $282.70M | 25.2% | +16.2% |
| Rest of World | $201.50M | $177.80M | $165.50M | $167.60M | $169.00M | $150.20M | $143.30M | $148.60M | $144.30M | $135.80M | $132.10M | $136.10M | 11.6% | +19.2% |
| Japan | $96.40M | $90.60M | $87.50M | $90.10M | $95.30M | $81.80M | $85.90M | $81.40M | $86.50M | $86.00M | $99.30M | $84.90M | 5.5% | +1.2% |
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Transcatheter Aortic Valve Replacement | $1.26B | $1.20B | $1.16B | $1.15B | $1.13B | $1.05B | $1.04B | $1.02B | $1.04B | $1.01B | $979.40M | $960.90M | 72.3% | +11.3% |
| Surgical | $284.10M | $276.20M | – | – | $266.80M | $250.90M | – | – | – | – | – | – | 16.3% | +6.5% |
| Transcatheter Mitral and Tricuspid Therapies | $198.60M | $175.10M | $155.70M | $145.20M | $134.50M | $115.20M | $105.10M | $91.10M | $83.00M | $72.90M | $56.00M | $52.40M | 11.4% | +47.7% |
| Critical Care | – | – | – | – | – | – | – | – | – | $251.30M | $250.50M | $221.00M | – | – |
| Surgical Structural Heart | – | – | $253.60M | $258.00M | $266.80M | $250.90M | $244.40M | $240.00M | $247.80M | $249.10M | $231.00M | $230.10M | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | – | – | – | – | – | – | – | $804.60M | $816.80M | $940.70M | $1.31B | $735.90M | – | – |
| Europe | – | – | – | – | – | – | – | $319.80M | $335.60M | $367.80M | $456.80M | $286.50M | – | – |
| Japan | – | – | – | – | – | – | – | $81.40M | $87.40M | $110.80M | $186.00M | $85.80M | – | – |
| Rest of World | – | – | – | – | – | – | – | $148.60M | $146.10M | $178.90M | $313.30M | $135.20M | – | – |
From the segment and revenue-disaggregation notes of Edwards Lifesciences's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.